Topics:
Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Bone Marrow Transplant • Hematology
Should post-transplant cyclophosphamide be utilized for all matched unrelated donor peripheral blood stem cell transplants for hematologic malignancy?
If not, how do you choose GVHD prophylaxis regimen? Is there a preference?
Answer from: at Academic Institution
In myeloablative transplantation, PTCY did not have an advantage over Tac/MTX as demonstrated in the BMT-CTN 1301 study which compared PTCY, Tac/MTX, and T cell depletion (Luznik et al., PMID 34855460). One caveat is that in this trial, PTCY based prophylaxis did not include Tac or Tac/MMF.BMT-CTN 1...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
I agree with Dr. @Antin.
Regarding the BMT-CTN 1301, while PTCy did not show superiority over Tac/MTX, we already probably know that PTCy alone (without Tac/MMF) is insufficient to mitigate the risk of GVHD.
We are eagerly awaiting the final results of the phase 3 BMT-CTN 1703 (PROGRESS III; PTCy/...